Journal
ACS SENSORS
Volume 8, Issue 3, Pages 1085-1100Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acssensors.2c02105
Keywords
localized surface plasmon resonance; nanoplasmonic sensor; interfacial charge transfer; high-throughput assay; microRNA; unprocessed plasma; pancreatic cancer; early detection
Ask authors/readers for more resources
In this study, an advanced nanoplasmonic sensor was developed for the sensitive and amplification-free detection of microRNAs in unprocessed plasma microsamples. The sensor utilized specially designed -ssDNA receptors attached to gold triangular nanoprisms to achieve highly specific detection. The sensor showed an attomolar limit of detection in human plasma and enabled high-throughput assay in a multiwell plate format. The performance of the sensor was validated using clinical samples, demonstrating its ability to differentiate pancreatic ductal adenocarcinoma (PDAC) from other conditions and determine PDAC stages. Furthermore, the sensor showed potential in monitoring microRNA changes in PDAC patients before and after surgery.
Pancreatic ductal adenocarcinoma (PDAC) is a deadly malignancy that is often detected at an advanced stage. Earlier diagnosis of PDAC is key to reducing mortality. Circulating biomarkers such as microRNAs are gaining interest, but existing technologies require large sample volumes, amplification steps, extensive biofluid processing, lack sensitivity, and are low-throughput. Here, we present an advanced nanoplasmonic sensor for the highly sensitive, amplification-free detection and quantification of microRNAs (microRNA-10b, microRNA-let7a) from unprocessed plasma microsamples. The sensor construct utilizes uniquely designed -ssDNA receptors attached to gold triangular nanoprisms, which display unique localized surface plasmon resonance (LSPR) properties, in a multiwell plate format. The formation of -ssDNA/microRNA duplex controls the nanostructure- biomolecule interfacial electronic interactions to promote the charge transfer/exciton delocalization processes and enhance the LSPR responses to achieve attomolar (10-18 M) limit of detection (LOD) in human plasma. This improve LOD allows the fabrication of a high-throughput assay in a 384-well plate format. The performance of nanoplasmonic sensors for microRNA detection was further assessed by comparing with the qRT-PCR assay of 15 PDAC patient plasma samples that shows a positive correlation between these two assays with the Pearson correlation coefficient value >0.86. Evaluation of >170 clinical samples reveals that oncogenic microRNA-10b and tumor suppressor microRNA-let7a levels can individually differentiate PDAC from chronic pancreatitis and normal controls with >94% sensitivity and >94% specificity at a 95% confidence interval (CI). Furthermore, combining both oncogenic and tumor suppressor microRNA levels significantly improves differentiation of PDAC stages I and II versus III and IV with >91% and 87% sensitivity and specificity, respectively, in comparison to the sensitivity and specificity values for individual microRNAs. Moreover, we show that the level of microRNAs varies substantially in pre-and post-surgery PDAC patients (n = 75). Taken together, this ultrasensitive nanoplasmonic sensor with excellent sensitivity and specificity is capable of assaying multiple biomarkers simultaneously and may facilitate early detection of PDAC to improve patient care.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available